Company intelligence / Profile preview

Prenetics

Hong Kong, Hong Kong

Ownership: Private
Development stage: Other

Overview

Insighta's multi-cancer early detection test Presight began clinical trials in 2024, with plans to test for more than 10 types of cancer with a single blood test by 2027

Therapeutic areas: Oncology
Modalities: DNA testingNext-generation sequencingLiquid biopsy
Industry: Molecular Diagnostics

Partnerships

David Beckham (IM8 co-founder)Dennis Lo (Insighta co-founder)Chinese University of Hong Kong (Insighta joint venture)

Beyond the preview

Go deeper on Prenetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prenetics.

Explore the full profile